ACC 24 Late-Breaker Discussion: The ARISE-HF Trial

ACC 2024 - Late-breaker host Dr. Harriette Van Spall (McMaster University, CA) sits down with Dr. James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc).
This phase 3 multicenter, randomized, placebo-controlled, 2-part study evaluated the safety and efficacy of an aldose reductase inhibitor (ARI), AT-001, in patients with diabetic cardiomyopathy. Findings presented first at ACC.24 showed that AT-001 was safe and well-tolerated but did not result in a statistically significant difference in peak VO2 in patients with diabetic cardiomyopathy and reduced exercise capacity, however, it should be noted that the participants of ARISE-HF had well controlled type II diabetes mellitus (A1c=6.98%) which might not reflect outcomes in individuals with diabetic cardiomyopathy more generally.
Recorded remotely from Boston and Hamilton, 2024.
Support: This is an independent content produced by Radcliffe Cardiology.
Editor: Mirjam Boros
Videographer: Mike Knight, Tom Green
Visit Radcliffe Cardiology: www.radcliffecardiology.com/
Visit Radcliffe Vascular: www.radcliffevascular.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: x.com/radcliffeCARDIO